HIV and the brain: from AIDS to old age by Haddow, LJ et al.
s24  © Royal College of Physicians, 2013. All rights reserved.
 ■ NEUROLOGY  Clinical Medicine  2013, Vol 13, No 6: s24–s28
ABSTRACT – The field of HIV medicine has changed rapidly 
in the last two decades since effective and tolerable antiret-
roviral treatment became available. As a result, although 
classical opportunistic infections of the brain have become 
less common, clinicians need to be aware of a wider range of 
acute and chronic complications of HIV and its treatment. In 
this article, we summarise major opportunistic infections, 
immune reconstitution inflammatory syndrome, HIV-
associated neurocognitive disorders, and cerebrovascular 
disease in HIV positive patients. We also emphasise the pre-
ventability and reversibility of most of the central nervous 
system complications of HIV, and hence the importance of 
early diagnosis of HIV and involvement of clinicians with 
special expertise in HIV medicine.
KEY WORDS: HIV, AIDS, HAART, IRIS, neurocognitive disor-
ders, cerebrovascular disease
Epidemiology
Highly active antiretroviral therapy (HAART) has radically 
altered the prognosis for human immunodeficiency virus (HIV) 
positive (HIV+) people since the mid-1990s. There is, however, 
little evidence for reduced incidence of HIV infection in most 
countries (including the UK),1 and increased survival has led to 
a higher prevalence. There are now around 100,000 patients 
living with HIV in the UK2 and 34 million worldwide.3 Healthcare 
workers in the UK are increasingly likely to encounter HIV+ 
patients who are receiving HAART, who do not have severe 
immunodeficiency, or who are older (around 22% of those in 
care are aged over 50 years)2 and therefore are more likely to 
have age-related comorbidities and polypharmacy. Furthermore, 
changing practice towards HAART initiation at higher CD4 
counts can prevent most complications of immunodeficiency in 
HIV+ patients who are diagnosed and under care. As a result, 
patients who do present with opportunistic infections (OIs) of 
the brain are more likely to have previously undiagnosed HIV, 
and clinicians need to be vigilant and carry out HIV testing 
without unnecessary delay. This article summarises the latest 
changes in the investigation and management of people with 
neurological conditions in the HIV+  population.
Major opportunistic infections of the central 
nervous system
Fig 1 shows the declining incidence rates of cryptococcal menin-
gitis (CM), progressive multifocal leukoencephalopathy (PML), 
toxoplasmosis of the brain and HIV encephalopathy (HIVE) in 
the UK from 1996 to 2007.4 Despite this overall decline in inci-
dence, it is essential that clinicians are vigilant to the possibility 
of undiagnosed HIV in patients who have acute neurological 
symptoms; failure to diagnose HIV early may confound diag-
nosis and lead to an increased risk of disability or death. The UK 
National Guidelines for HIV Testing 2008 recommend HIV 
testing for all medical admissions where the local prevalence 
exceeds 2 in 1,000, all patients in certain higher-risk groups and 
all patients with ‘indicator diseases’, many of which are neuro-
logical in nature (Table 1).5
Physicians should also be aware of the presenting features and 
initial management of central nervous system (CNS) OI;6 these 
are summarised in Table 2. Importantly, there is survival benefit 
from prompt diagnosis and treatment. The British HIV 
Association (BHIVA) recommends that patients with suspected 
acquired immunodeficiency syndrome (AIDS)-related condi-
tions are transferred to an HIV specialist centre within 24 hours.
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Fig 1. Rates of four AIDS-defining central nervous system conditions in 
UK HIV+ adults during the first 10 years of highly active antiretroviral 
therapy (estimates from UK Collaborative HIV Cohorts data).4 
CM = cryptococcal meningoencephalitis; HIV = human immunodeficiency 
virus; HIVE = HIV encephalopathy; PML = progressive multifocal 
leukoencephalopathy; Toxo = toxoplasmosis of the brain.
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initiating HAART after just a 2-week wait. Those studies were 
mainly of patients who had opportunistic lung disease, and CNS 
disease may be an exception to the rule that more rapid initia-
tion of HAART improves outcome. Two randomised studies 
(one unpublished) of the timing of anti-retroviral therapy 
(ART) in cryptococcal meningitis have suggested that starting 
HAART earlier leads to higher mortality.11
Rates of unmasking CNS IRIS are highly dependent on the 
underlying prevalence of the OI and the intensity of pre-HAART 
investigation. It is estimated that 0.5–1% of patients without 
known cryptococcosis starting HAART in high-prevalence African 
countries develop unmasking IRIS related to this infection, a con-
dition of very high mortality,12 although rates are likely to be 
lower in the UK. The ideal balance between detailed pre-HAART 
investigation to prevent unmasking IRIS of untreated OI and the 
need to start therapy in severely immunodeficient patients has yet 
to be determined (other than the proven mortality benefit of 
screening for serum cryptococcal antigen in those with low CD4 
counts in regions of high cryptococcosis prevalence).13
The optimal treatment of IRIS is not clear. Although systemic 
corticosteroids are often used to reduce inflammation and 
oedema in the enclosed intracranial compartment, the only 
clinical trial on their use (which showed a benefit in mild-to-
moderate TB IRIS) specifically excluded those with CNS involve-
ment.14 It is possible that immunosuppressive therapy might 
have a negative impact on outcome, especially in CM where 
there is a high fungal burden and steroids could delay clearance 
of the pathogen. In cryptococcal IRIS, rising intra-cranial pres-
sure (ICP) may be recalcitrant,15 and controlling pressure with 
repeated therapeutic lumbar puncture or shunting is necessary. 
Cessation of HAART is not recommended except to reduce the 
immune response as a temporary life-saving measure or when 
the diagnosis is unclear and drug toxicity is suspected.
An unusual complication of immune reconstitution in HIV is 
the emergence of lymphocytic cerebritis without an underlying 
opportunistic infection.16,17 Clinically, this may present with 
confusion, focal neurology, reduced conscious level and seizures, 
occurring weeks to months after HAART initiation, and death 
often ensues. Neuroimaging may show large flitting T2 hyper-
intense white matter lesions, and histology shows a CD8+ lym-
phocytic infiltrate in the brain. It is believed that an immuno-
logical response to HIV underlies the pathogenesis. Several of 
the reported cases were fatal and treatment with systemic corti-
costeroids may be beneficial.16,17
HIV-associated neurocognitive disorders
The direct neurovirulence of HIV has been known for over 25 
years. In 1988, Price and Brew18 described and graded the clinical 
syndrome of AIDS Dementia Complex (ADC, also known as 
HIV-associated dementia [HAD]). This is a progressive dementia 
in which cognitive symptoms, mainly concentration impair-
ment, memory loss and mental slowing, are frequently accompa-
nied by motor signs and behavioural symptoms such as apathy, 
mood disorders and psychosis. HAART is effective in reducing 
Immune reconstitution inflammatory syndrome
Immune reconstitution inflammatory syndrome (IRIS) is 
common in patients starting HAART who have advanced 
immunodeficiency and a pre-existing OI. The syndrome is 
believed to be the result of rapid restoration of pathogen-specific 
immune responses in the absence of sufficient regulatory 
immune activity. This leads to worsening signs and symptoms of 
a known infection (‘paradoxical’ IRIS) or to the clinical presen-
tation of a previously occult infection (‘unmasking’ IRIS), often 
with rapidly progressing or atypical clinical features.7 A meta-
analysis of rates of paradoxical IRIS found that around 20% of 
patients with known cryptococcosis and 17% of those with 
known PML upon starting HAART develop paradoxical IRIS 
related to the original OI.8 Delaying the start of HAART by 
weeks or months after starting treatment for an OI appears to 
reduce the incidence of IRIS, but studies of patients with tuber-
culosis (TB) and other infections9,10 found survival benefit in 
Table 1. Indications for HIV testing that are potentially applicable 
to patients with neurological conditions. Adapted with permission 
from UK National Guidelines for HIV Testing (2008).5
Category of testing Situation where HIV testing is indicated
Universal HIV testing is 
recommended in the 
following healthcare 
services
Services for those diagnosed with 
tuberculosis, chronic viral hepatitis or 
lymphoma
All patients registering in 
general practice 
Where diagnosed HIV prevalence in the 
local population exceeds 2 in 1,000
All general medical 
admissions
Where diagnosed HIV prevalence in the 
local population exceeds 2 in 1,000
Patients presenting for 
care where HIV enters the 
differential diagnosis, 
including (but not limited 
to) the following indicator 
diseases
Cerebral toxoplasmosis
Aseptic meningitis or encephalitis
Primary cerebral lymphoma 
Cerebral abscess
Cryptococcal meningitis 
Space-occupying lesion of unknown cause
Progressive multifocal leucoencephalopathy
Guillain–Barré syndrome
Transverse myelitis
Peripheral neuropathy
Dementia
Leucoencephalopathy
Mononucleosis-like syndrome
Pyrexia of unknown origin
Lymphadenopathy of unknown cause
High-risk groups* Men who have disclosed sexual contact 
with other men
Men and women known to be from a 
country of high HIV prevalence (>1%)
Patients reporting a history of injecting 
drug use
HIV = human immunodeficiency virus. 
*This is not an exhaustive list of high-risk groups.
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Table 2. Summary of important clinical features of major HIV-related central nervous system opportunistic infections. Adapted with permission 
from British HIV Association guidelines for the treatment of opportunistic infections.6
Condition Typical presenting 
symptoms
Neuroimaging findings Diagnostic test First-line treatment
Progressive 
multifocal 
leucoencephalo -
pathy
Focal neurology, often 
indicating multiple lesions, 
altered mental status, 
seizures. Progressive over 
weeks or months. No 
constitutional symptoms
Bilateral, asymmetric, well-
demarcated, non-enhancing T2 
hyperintense white matter 
lesions, which may be large in 
size. Usually no oedema or 
mass effect except in IRIS
Detection of JC virus nucleic 
acid in CSF, supported by 
clinical and neuroimaging 
appearances
No specific treatment. Initiate 
HAART
Cerebral 
toxoplasmosis
Focal neurological signs 
and symptoms progressing 
over days to weeks, 
reduced consciousness 
level, seizures, confusion 
or odd behaviour, 
symptoms of raised ICP
Multiple ring-enhancing 
masses (abscesses), often at 
the grey-white interface or 
deep grey matter. Frequently 
significant oedema and mass 
effect
Diagnosis usually based on 
contrast-enhanced 
neuroimaging appearances, 
supported by clinical response 
to anti-parasitic therapy
Occasionally supported by 
nuclear medicine brain 
imaging or detection of 
Toxoplasma nucleic acid in CSF 
(lumbar puncture is often 
contraindicated)
Induction: oral sulphadiazine 
(15 mg/kg four times daily) 
and pyrimethamine (loading 
dose 200 mg then 50–75 mg 
daily) with folinic acid (10–15 
mg daily) for 6 weeks
Maintenance: sulphadiazine 
(500 mg four times daily) and 
pyrimethamine (25 mg daily) 
with folinic acid (10 mg daily)
Cryptococcal 
meningitis
Headache, fever, features 
of raised ICP including 
drowsiness and reduced 
level of consciousness, 
meningism, pulmonary or 
cutaneous manifestations 
of cryptococcosis. Onset 
may initially be insidious
Occasional small or large 
space-occupying lesions, which 
may be multiple. Variable 
degree of associated 
inflammation and oedema. 
Features of raised ICP
Detection of typical 
capsulated yeasts in CSF with 
appropriate staining (eg India 
ink); detection of cryptococcal 
antigen testing in CSF; fungal 
culture of CSF. CSF white cell 
count may be low in severely 
immuno-deficient patients; 
CSF protein usually high
Induction: liposomal 
amphotericin B (4 mg/kg/day) 
and 5-flucytosine (100 mg/kg/
day) for 2 weeks.
Maintenance: fluconazole 
(400 mg daily) for 8 weeks
Reduction of ICP by serial CSF 
tap or shunting is an essential 
adjunct to antifungal 
therapy38
Cytomegalovirus 
encephalitis
Highly variable. Subacute 
apathy, disorientation, 
cranial nerve palsies, often 
accompanied by retinitis 
or polyradiculitis
Bilateral, symmetrical, diffuse, 
T2 hyperintense white matter 
lesions. Periventricular 
enhancement. Neuroimaging 
may be normal
Detection of cytomegalovirus 
nucleic acid in CSF, supported 
by neuroimaging findings and 
frequent coexistence of retinal 
lesions. Serology and plasma 
detection of viral nucleic acid 
are usually unhelpful
Induction: IV ganciclovir 
(5 mg/kg twice daily) for 
3 weeks
Maintenance: IV ganciclovir 
(5 mg/kg daily) or oral 
valganciclovir (900 mg daily)
HIV 
encephalopathy
Progressive global 
cognitive impairment, 
apathy, psychomotor 
slowing, depression, 
psychosis. Often 
accompanied by motor 
signs caused by vacuolar 
myelopathy
Bilateral, symmetrical, diffuse, 
T2 hyperintense white matter 
lesions. Neuroimaging may be 
normal. May be difficult to 
distinguish from other viral 
encephalitis, eg 
cytomegalovirus or PML
Exclusion of other causes of 
viral encephalitis. Detection of 
high levels of HIV nucleic acid 
in CSF relative to plasma 
levels, supported by 
neuroimaging and clinical 
findings
Initiate HAART
CSF = cerebrospinal fluid; HAART = highly active antiretroviral therapy; HIV = human immunodeficiency virus; ICP = intracranial pressure; IRIS = immune reconstitution 
inflammatory syndrome; IV = intravenous; JC virus = John Cunningham virus; PML = progressive multifocal leucoencephalopathy.
the rate of onset of encephalopathy and there has been a rapid 
decline in the incidence of HAD since 1997.4 Furthermore, sev-
eral observational studies have shown rates of resolution of 
dementia on HAART of 30–70%.19 Thus HAD is one of the few 
types of dementia that is both preventable and reversible.
Several areas of uncertainty make HIV-associated neuro-
cognitive disorders (HAND) a field of ongoing research and 
discovery. First, not all HAD significantly improves on HAART. 
There is likely to be irreversible neuronal loss, despite suppres-
sion of the virus, together with reduction of the inflammatory 
response, as evidenced by chronic cerebral atrophy in affected 
patients. A low nadir CD4+ lymphocyte count in the past is 
associated with persistent atrophy, even in those without signifi-
cant cognitive impairment. An important question for HIV cli-
nicians is which patients with HAD will experience the greatest 
improvement in neurocognitive function on HAART and there 
are no specific biomarkers to predict prognosis.
Second, there is evidence that mild-to-moderate HAND is 
common in patients receiving HAART; it remains unclear why 
this should be the case and whether it is of clinical importance to 
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differences in target cell tropism in the virus itself have also been 
considered as possible explanations for the phenomena described 
above. Finally, there is evidence that antiretroviral drugs themselves 
may be neurotoxic.31 Concerns that antiretroviral toxicity might 
negatively affect cognition were supported in a trial in which stop-
ping treatment was associated with improvements in assessments 
of cognitive function,32 though increased mortality is associated 
with even short, structured ART interruptions.33
Cerebrovascular disease
There is considerable epidemiological evidence for an increased 
risk of acute coronary events in HIV+ patients.34 While the role 
of confounders in this association cannot be ignored, there is 
mounting support for a role for a low-grade chronic inflamma-
tory state and endothelial dysfunction in HIV+ patients, even 
when treated with virally suppressive HAART. A recent review35 
and a Danish study36 support the hypothesis that HIV infection 
can cause ischaemic stroke. This is distinct from the embolic 
complications of intravenous drug use, from OIs that present 
with stroke-like syndromes and from the phenomenon of an 
immunologically driven or infectious cerebral arteritis (caused 
by TB or varicella zoster virus), all of which are now seen rela-
tively rarely in HIV+ patients in the UK. The epidemiological 
evidence for a higher stroke risk in HIV+ people is problematic, 
particularly because of high rates of cigarette, cocaine and 
amphetamine use in young HIV+ adults. Furthermore, protease 
inhibitors form part of the treatment of a large proportion of 
HIV+ patients, and prolonged use of drugs of this class is associ-
ated with a rising incidence of stroke.37 Small-vessel cerebrovas-
cular disease has not been studied in HIV, but indirect evidence 
of its occurrence comes from the presence, on brain magnetic 
resonance imaging, of white matter lesions of similar character 
and distribution to those seen in normal ageing and in HIV-
negative adults with high cerebrovascular risk profiles.
What does the future hold for HIV and the brain?
There has been dramatic progress in increasing the life expectancy 
and quality of life of HIV+ patients in the past 15 years, largely due 
to HAART and the resulting decrease in the complications of 
immunodeficiency. The incidence of OIs of the CNS is likely to 
continue to decline in regions where HAART is available, but doc-
tors must remain vigilant to the possibility of undiagnosed HIV in 
any patient with a neurological presentation. The prognosis is good, 
even in the most severely ill patients with CNS disease. It is vital, 
therefore, to investigate and treat this disease aggressively and to 
enlist the help of colleagues with HIV expertise early on. In patients 
who are diagnosed with HIV early and treated prior to developing 
severe immunodeficiency, healthy ageing is now a real possibility. 
Cohort studies in the UK and elsewhere are currently measuring the 
incidence of neurodegenerative and cerebrovascular diseases in 
HIV+ people aged 50 and above. At present, it is not clear whether 
they will  experience a higher rate of dementia, stroke or small vessel 
cerebrovascular disease than the general population.
those living with HIV. In two large studies, one of virologically 
suppressed HIV+ patients from Switzerland20 and one of a more 
diverse HIV+ sample in the USA with only 41% with an undetec-
table viral load,21 around 50% had neurocognitive impairment, 
even though most were asymptomatic and without any impact 
on activities of daily living. Studies of HAND prevalence are 
dogged by methodological concerns around patient selection, 
generalisation between populations, confounding factors and the 
lack of gold-standard methods for assessment or classification. 
Neuropsychological evaluation tools might be over-sensitive 
because 15–20% of the HIV-negative background population 
would be ‘impaired’ under some published definitions. Also, neu-
ropsychological tests are complex and likely to be culturally and 
educationally biased: in Europe, a large number of HIV+ patients 
are migrants and in the US many are low-income African-
Americans with relatively poor education. Both of these demo-
graphic groups show lower levels of performance on standard 
neuropsychological testing.22,23 Confounding factors that have 
increased prevalence in HIV+ patients and are associated with 
poorer neuropsychological scores include hepatitis C infection, 
drug and alcohol use, and depression. In our practice, milder 
cognitive impairment in HIV is often attributable to a number of 
possible aetiologies and the diagnosis is rarely  clearcut. 
Third, there are concerns that there may be ongoing replication 
of HIV within microglia and other virally infected cells in the 
CNS, even when peripheral virological suppression and immuno-
logical recovery have been achieved. The CNS is a relatively sepa-
rate physiological compartment from both an immunological and 
a pharmacological perspective. It is reported that 8–10% of neu-
rologically stable patients with an undetectable plasma viral load 
have quantifiable levels of HIV RNA in their cerebrospinal fluid 
(CSF),24 known as ‘CSF viral escape’. The clinical consequences 
and natural history of this phenomenon are unknown, but the 
tendency to detect such patients after repeated investigation of 
unexplained neurology has led to several case reports.25,26 Current 
European and British HIV treatment guidelines recommend 
altering HAART in patients who have a detectable CSF viral load 
when the plasma viral load is undetectable.27,28 Checking for 
genotypic resistance in CSF viral isolates is important, as viral 
resistance in the CSF may differ from that detected in the plasma.
The failure of some severely impaired patients to improve on 
HAART, the high prevalence of mild cognitive impairment in 
patients receiving treatment and the frequency of patients with 
detectable HIV RNA in CSF have all led to an interest in the ability 
of different antiretroviral agents to penetrate the CNS. Two 
US-based groups have developed and evaluated scores29,30 to esti-
mate the likelihood of achieving virological control in the CNS. 
Unfortunately, both scores are based on a combination of observa-
tional data and pharmacokinetic principles, and although they can 
guide drug choice in treated and untreated patients with neurocog-
nitive impairment, or in those with CNS viral escape, this approach 
has not been successfully evaluated in a randomised trial. (A recent 
attempt to conduct such a trial failed to recruit sufficient numbers 
of participants.) Genetic differences in genes coding for host 
endothelial transporter molecules at the blood-brain barrier and 
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